Dossiers d'AMM à étudier par le Comité Technique des Spécialités Pharmaceutiques du 15/12/2022.
Pour ce comité technique, l’ordre de passage des dossiers sera comme suit .
Spécialités Pharmaceutiques fabriquées localement :
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | DATE Rapport |
1 | GALAMOX | AMOXICILLINE | 500 mg | Gélule | B/12 | GALPHARMA | E | N | 19/08/2022 |
2 | GALAMOX | AMOXICILLINE | 500 mg | Comprimé dispersible | B/12 | GALPHARMA | E | N | 19/08/2022 |
3 | BETANYL | SULFATE DE TERBUTALINE | 5 mg/2ml | Solution pour inhalation | B/10unidoses | UNIMED | E | N | 09/09/2022 |
4 | DULOX | DULOXETINE | 30 mg | Gélule gastrorésistante | FL/28 | IBN AL BAYTAR | E | N | 12/09/2022 |
5 | DULOX | DULOXETINE | 60 mg | Gélule gastrorésistante | FL/28 | IBN AL BAYTAR | E | N | 12/09/2022 |
6 | DAFLON | DIOSMINE+ HESPERIDINE | 1000 mg | Comprimé pelliculé | B/30 | TERIAK | C | N | 22/09/2022 |
7 | RIABAL | PRIFINIUM | 30 mg | Comprimé pelliculé | B/20 | IBN AL BAYTAR | I | N | 03/10/2022 |
8 | VITAPRED 1 | PREDNISOLONE | 1 mg/ml | solution buvable | B/1FL/50ML | TAHA PHARMA | E | N | 05/10/2022 |
9 | ACIRYL | PREGABALINE | 300 mg | gélule | B/60 | OPALIA PHARMA | V | N | 12/10/2022 |
10 | APYROSIS DOUBLE ACTION CITRON | Alginates+carbonate de calcium+bicarbonate de sodium | 500mg/213mg/325mg | susponsion buvable | B/20 S | OPALIA PHARMA | E | N | 12/10/2022 |
11 | APYROSIS DOUBLE ACTION MENTHE | Alginates+carbonate de calcium+bicarbonate de sodium | 500mg/213mg/325mg | susponsion buvable | B/20 S | OPALIA PHARMA | E | N | 12/10/2022 |
12 | ROSACNE | ACIDE AZELAIQUE | 15% | GEL dermique | T/30 g | SIMED | C | N | 14/10/2022 |
13 | BIFOR 5 | TADALAFIL | 5 mg | Comprimé pelliculé | B/30 | PHILADELPHIA PHARMA | C | N | 16/11/2022 |
14 | ENOMERAL 40 | ESOMEPRAZOLE | 40 mg | Gélule gastrorésistante | B/07 | TAHA PHARMA | E | N | 25/11/2022 |
15 | ENOMERAL 40 | ESOMEPRAZOLE | 40 mg | Gélule gastrorésistante | B/14 | TAHA PHARMA | E | N | 25/11/2022 |
16 | ENOMERAL 40 | ESOMEPRAZOLE | 40 mg | Gélule gastrorésistante | B/28 | TAHA PHARMA | E | N | 25/11/2022 |
* Audit medicaments fabriqués localement (2ème passage)
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | DATE Rapport |
1 | TELMYCOR-AM | TELMISARTAN+ AMLODIPINE | 40 mg/5 mg | comprimé | B/30 | THERA | E | N | 02/12/2022 |
2 | TELMYCOR-AM | TELMISARTAN+ AMLODIPINE | 80 mg/5 mg | comprimé | B/30 | THERA | E | N | 02/12/2022 |
3 | TELMYCOR-AM | TELMISARTAN+ AMLODIPINE | 40 mg/10 mg | comprimé | B/30 | THERA | E | N | 02/12/2022 |
4 | TELMYCOR-AM | TELMISARTAN+ AMLODIPINE | 80 mg/10 mg | comprimé | B/30 | THERA | E | N | 02/12/2022 |
Spécialités Pharmaceutiques importées :
* Produits déjà évalués lors des derniers Comités Techniques
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de demande | date du courrier |
1 | REDEX | TADALAFIL | 20 mg | Comprimé pelliculé | B/2 | AL-TAQADDOM PHARMACEUTICAL INDUSTRIES | C | N | 09/06/2022 |
2 | REDEX | TADALAFIL | 5 mg | Comprimé pelliculé | B/30 | AL-TAQADDOM PHARMACEUTICAL INDUSTRIES | C | N | 09/06/2022 |
3 | REDEX | TADALAFIL | 10 mg | Comprimé pelliculé | B/2 | AL-TAQADDOM PHARMACEUTICAL INDUSTRIES | C | N | 09/06/2022 |
4 | ZYDEX HC | ACIDE FUSIDIQUE + HYDROCORTISONE | CREME DERMIQUE | T/15 G | BEIT JALA PHARMACEUTICAL CO | E | N | 22/06/2022 | |
5 | REAGILA | CHLORHYDRATE DE CARIPRAZINE | 4,5 mg | gélule | B/30 | GEDEON RICHTER | N | 18/07/2022 | |
6 | REAGILA | CHLORHYDRATE DE CARIPRAZINE | 6 mg | gélule | B/30 | GEDEON RICHTER | N | 18/07/2022 | |
7 | REAGILA | CHLORHYDRATE DE CARIPRAZINE | 3 mg | gélule | B/30 | GEDEON RICHTER | N | 18/07/2022 | |
8 | REAGILA | CHLORHYDRATE DE CARIPRAZINE | 1,5 mg | gélule | B/30 | GEDEON RICHTER | N | 18/07/2022 | |
9 | FERPLEX | FER | 40 mg / 15ml | SOL BUV | B/10 monodoses/15 ML | ITALFARMACO S.p.A ITALIA | E | N | 26/07/2022 |
10 | LUCENTIS | RANIBIZUMAB | 10 mg/ml | SOL INJ | FL/1 | NOVARTIS | E | V | 21/07/2022 |
11 | HEMLIBRA | EMICIZUMAB | 30mg/ml | SOL INJ | B/1FL/1ML | ROCHE PHARMA AG | V | 03/08/2022 | |
12 | HEMLIBRA | EMICIZUMAB | 105mg/0,7ml | SOL INJ | B/1FL/3ML | ROCHE PHARMA AG | V | 04/08/2022 | |
13 | HEMLIBRA | EMICIZUMAB | 150mg/ml | SOL INJ | B/1FL/1ML | ROCHE PHARMA AG | V | 05/08/2022 | |
14 | HEMLIBRA | EMICIZUMAB | 60mg/0,4ml | SOL INJ | B/1FL/3ML | ROCHE PHARMA AG | V | 06/08/2022 | |
15 | FORLAX | POLYETHYLENE GLYCOL | 4 gr | PDRE PR SOL ORAL | B/20 | IPSEN CONSUMER HEALTHCARE | C | T | 09/09/2022 |
16 | ENTEROGERMINA | SPORES DE BACILLUS CLAUSII POLYANTIBIO-RÉSISTANT | 4 milliards/5ml | SUSP BUV | B/10FL/5ml | SANOFI-AVENTIS S.p.A | I | N | 19/09/2022 |
17 | JARDIANCE | EMPAGLIFLOZINE | 10 MG | COMP | B/30 | BOEHRINGER INGELHEIM | E | V | 29/09/2022 |
18 | JARDIANCE | EMPAGLIFLOZINE | 25 MG | COMP | B/30 | BOEHRINGER INGELHEIM | E | V | 29/09/2022 |
19 | DUOPLAVIN | CLOPIDOGREL+ ACIDE ACETYLSALICYLIQUE | 75 mg/100 mg | Comprimé pelliculé | B/28 | SANOFI PHARMA B.M.S SNC | E | N | 02/11/2022 |
20 | ERBITUX 100 | CETUXIMAB | 5 mg/ml | SOL INJ PR PERF | B/1 Flacon/20 ml | MERCK EUROPE B.V | V | T | 09/11/2022 |
21 | ERBITUX 500 | CETUXIMAB | 5 mg/ml | SOL INJ PR PERF | B/1 Flacon/100 ml | MERCK EUROPE B.V | V | T | 09/11/2022 |
22 | DEXMEDETOMIDINE EVER PHARMA | Dexmedetomidine | 200µg/2ml (100µg/ml) | SOL INJ PR PERF | B/5FL/2ML | EVER Valinject GmbH | N | 16/11/2022 | |
23 | DEXMEDETOMIDINE EVER PHARMA | Dexmedetomidine | 400µg/4ml (100µg/ml) | SOL INJ PR PERF | B/5FL/4ML | EVER Valinject GmbH | N | 16/11/2022 | |
24 | DEXMEDETOMIDINE EVER PHARMA | Dexmedetomidine | 1000µg/10ml (100µg/ml) | SOL INJ PR PERF | B/5FL/10ML | EVER Valinject GmbH | N | 16/11/2022 | |
25 | HEBERPROT-P 75 | FACTEUR DE CROISSANCE EPIDERMIQUE RECOMBINANT | 75 mcg | PDRE PR PREP INJ | B/6 flacons | CIGB CUBA | E | N | 09/11/2022 |
26 | FIXAPROST | LATANOPROST+TIMOLOL | 50 µg/ml | COLLYRE | B/30 unidoses | THEA | E | N | 29/11/2022 |
27 | SKYRIZI | RISANKIZUMAB | 75 mg | SOL INJ | B/2 | ABBVIE DEUTSCHLAND Gmbh and Co.KG | N | 05/12/2022 | |
28 | VICTOZA | Liraglutide | 6mg/ml | SOL INJ | B/2 | NOVO-NORDISK DANEMARK | V | 08/12/2022 |
* Produits à évaluer pour la première fois au Comité Technique
N° | Médicament | DCI | Dosage | Forme Pharmaceutique | Présentation | TITULAIRE | VEIC | Type de la demande | DATE RE |
1 | POVIDEX | POVIDONE IODEE | 5% | SUP VAGINAL | B/12 | BEIT JALA Pharmaceutical Co | I | N | 21/09/2022 |
2 | LIPERCOSYL | ATORVASTATINE+PERINDOPRIL ARGININE | 40 MG/ 5MG | Gélule | B/30 | SERVIER | E | N | 21/09/2022 |
3 | LIPERCOSYL | ATORVASTATINE+PERINDOPRIL ARGININE | 20 MG/ 5MG | Gélule | B/30 | SERVIER | E | N | 21/09/2022 |
4 | LIPERCOSYL | ATORVASTATINE+PERINDOPRIL ARGININE | 10 MG/ 5MG | Gélule | B/30 | SERVIER | E | N | 21/09/2022 |
5 | LIPERCOSYL | ATORVASTATINE+PERINDOPRIL ARGININE | 40 MG/ 10MG | Gélule | B/30 | SERVIER | E | N | 21/09/2022 |
6 | LIPERCOSYL | ATORVASTATINE+PERINDOPRIL ARGININE | 20 MG/ 10MG | Gélule | B/30 | SERVIER | E | N | 21/09/2022 |
7 | LIPERCOSYL | ATORVASTATINE+PERINDOPRIL ARGININE | 10MG/10MG | ||||||
8 | VYZULTA | LATANOPTOSTENE BUNOD | 0.024% | COLLYRE | B/1FL | Baush & Lomb, Incorporated | N | 28/09/2022 | |
9 | TENORETIC | ATENOLOL+CHLORTALIDONE | 50mg/12.5mg | COMP PEL | B/30 | ATNAHS PHARMA NETHERLANDS B.V | E | T | 30/09/2022 |
10 | DEPAMIDE | VALPROMIDE | 300 MG | COMP PEL | B/30 | SANOFI AVENTIS France | V | V | CS 05/10/2022 |
11 | LUMIGAN | BIMATOPROST | 0.1 mg/ml | COLLYRE | B/1FL | ABBVIE DEUTSCHLAND Gmbh and Co.KG | E | N | 14/10/2022 |
12 | GANFORT | BIMATOPROST+TIMOLOL | 0.3MG/ML+5MG/ML | COLLYRE | B/1/3ML | ABBVIE DEUTSCHLAND Gmbh and Co.KG | E | T | 19/10/2022 |
13 | ISOSUPRA LIDOSE | ISOTRETINOINE | 8 MG | GELULLE | B/30 | SMB S.A | I | N | 04/11/2022 |
14 | OZURDEX | DEXAMETHASONE | 700 mcg | implant intravitréen | B/ 1 implant intravitréen | ABBVIE DEUTSCHLAND Gmbh and Co.KG | E | T | 08/11/2022 |
15 | ATOSIBAN EVER Pharma | ATOSIBAN | 37.5 mg/ 5 ml | SOL INJ PR PRF | B/1 flacon / 5ml | EVER Valinject GmbH | E | N | 16/11/2022 |
16 | ATOSIBAN EVER Pharma | ATOSIBAN | 75 mg/ 10 ml | SOL INJ PR PRF | B/1 flacon / 10ml | EVER Valinject GmbH | E | N | 16/11/2022 |
17 | ATOSIBAN EVER Pharma | ATOSIBAN | 6,75 mg/ 0,9 ml | SOL INJ PR PRF | B/1 flacon / 2 ml | EVER Valinject GmbH | E | N | 16/11/2022 |
18 | MYCOTEN VAGINAL CREAM | CLOTRIMAZOLE | 2% | CREME VAGINAL | T/20g | BEIT JALA Pharmaceutical Co | I | N | 16/11/2022 |
19 | MYCOTEN | CLOTRIMAZOLE | 500 mg | COMP VAGINAL | B/1 + Applicateur | BEIT JALA Pharmaceutical Co | E | N | 16/11/2022 |
20 | MYCOTEN | CLOTRIMAZOLE | 200 mg | COMP VAGINAL | B/3 + Applicateur | BEIT JALA Pharmaceutical Co | E | N | 16/11/2022 |
21 | PENTASA | MESALAZINE | 1 g | SUPPO | B/28 | FERRING GmbH | E | N | 28/11/2022 |